 |
Encouraging Results in Breast and Pancreatic Cancers for Patients Treated With Peregrine's Novel Immunotherapy Bavituximab Presented at ASCO
Jun 3, 2013
|
63.7 KB |
|
| |
TUSTIN, CA -- (Marketwired) -- 06/03/13 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) reported today that data was presented at the 2013 ASCO Annual Meeting from two clinical trials evaluating the company's lead clinical candidate bavituximab. In the first study presented, interim data from a Phase I trial evaluating bavituximab plus paclit...
|
|
Data Presented at ASCO Shows Promising 11.7 Month Median Overall Survival in Second-Line NSCLC Patients Treated With Peregrine Pharmaceuticals' Novel Immunotherapy Bavituximab
Jun 3, 2013
|
18.7 KB |
|
| |
TUSTIN, CA -- (Marketwired) -- 06/03/13 --
Peregrine Pharmaceuticals (NASDAQ: PPHM), today reported final data from its randomized, double-blind, placebo-controlled Phase II trial of bavituximab in patients with second-line non-small cell lung cancer (NSCLC). Final results from the Phase II trial showed an improvement in median overall survival...
|
|
Peregrine Pharmaceuticals Reaches Agreement With FDA on a Phase III Trial Design for Bavituximab in Second-Line Non-Small Cell Lung Cancer
May 20, 2013
|
17.1 KB |
|
| |
TUSTIN, CA -- (Marketwired) -- 05/20/13 --
Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Phase III registration trial design...
|
|
Peregrine Pharmaceuticals' Immunotherapy Bavituximab to Be Highlighted in Three Clinical Data Presentations at 2013 ASCO Annual Meeting
May 16, 2013
|
18.4 KB |
|
| |
TUSTIN, CA -- (Marketwired) -- 05/16/13 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the presentation of three clinical posters at the 2013 American Society of Clinical Oncology (ASCO) Annual Meetin...
|
|
Peregrine Announces Completion of Patient Enrollment in Breast Cancer Clinical Trial for Bavituximab
Apr 29, 2013
|
19.8 KB |
|
| |
TUSTIN, CA--(Marketwired - Apr 29, 2013) - Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the completion of patient enrollment in an i...
|
|
Data Presented at AACR Annual Meeting Support Targeted Immune Reactivation Mechanism and Potential of Peregrine's Bavituximab in Solid Tumor Therapy
Apr 10, 2013
|
60.7 KB |
|
| |
TUSTIN, CA -- (Marketwired) -- 04/10/13 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today highlighted data presented at the Annual Meeting of the American Association for Cancer Research (AACR). Data was presented...
|
|
Peregrine Announces Three Abstracts Accepted for Presentation at AACR 2013 Annual Meeting
Apr 1, 2013
|
17.6 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 04/01/13 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the acceptance of three preclinical abstracts scheduled for poster presentations at the 104th Annual Meeting of th...
|
|
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2013 Financial Results and Recent Developments
Mar 12, 2013
|
29.9 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 03/12/13 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the third quarter ended January 31, 2013 of fiscal year (FY) 2013 and provided an update on ...
|
|
Peregrine to Report Third Quarter Fiscal Year 2013 Financial Results After Market Close on March 12, 2013
Mar 5, 2013
|
13.7 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 03/05/13 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it will report financial results for the third quarter of the fiscal year (FY) 2013 on March 1...
|
|
Peregrine Announces Participation at Upcoming Investor Conferences
Feb 26, 2013
|
14.9 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 02/26/13 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that Steven W. King, president and chief executive officer, will participate at the following investor conferences...
|
|
Avid Bioservices to Highlight Recent Successes in Reducing Manufacturing Costs and Novel Ways of Controlling Critical Process Parameters That Lead to Consistent Product Quality at IBC'S Biopharmaceutical Development and Production Conference
Feb 26, 2013
|
18.7 KB |
|
| |
TUSTIN, CA and HUNTINGTON BEACH, CA -- (Marketwire) -- 02/26/13 --
Avid Bioservices, Inc., a subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced that it will present two posters at IBC's Biopharmaceutical Development & Production Conference to be held in Huntington Beach, California, February 26 - March 1, 2013. Avid w...
|
|
Peregrine Pharmaceuticals Updates Top-Line Data From Phase II Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer
Feb 19, 2013
|
20.0 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 02/19/13 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today reported data from its randomized, double-blind placebo-controlled Phase II trial of bavituximab in patients with second-line non-small cell lung cancer (NSCLC). Data from the trial has been updated based on completion of an earlier review of discrep...
|
|
Peregrine Pharmaceuticals Announces Results From Phase II Clinical Trial of Bavituximab in Stage IV Pancreatic Cancer
Feb 13, 2013
|
17.1 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 02/13/13 --
Peregrine Pharmaceuticals (NASDAQ: PPHM) today announced results from its 70 patient open-label, randomized Phase II clinical trial of bavituximab used in combination with gemcitabine in patients with previously untreated, advanced Stage IV pancreatic cancer. The trial included the enrollment of patient...
|
|
Peregrine Pharmaceuticals Provides Update on the Internal Review of Its Phase II Second-Line Non-Small Cell Lung Cancer Trial
Jan 7, 2013
|
17.7 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 01/07/13 --
Peregrine Pharmaceuticals, Inc.(NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today provided an update from its internal review of discrepancies from its Phase II randomized, double-blind placebo-controlled tr...
|
|
Peregrine Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement
Dec 11, 2012
|
14.0 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 12/11/12 --
Peregrine Pharmaceuticals (NASDAQ: PPHM) today announced that it has received a letter from The NASDAQ Stock Market LLC notifying the company that it has regained full compliance with the NASDAQ Capital Market's minimum bid price continued listing requirement.
The letter received today no...
|
|
Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2013 Financial Results and Recent Developments
Dec 10, 2012
|
29.9 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 12/10/12 --
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the second quarter ended October 31, 2012 of fiscal year (FY) 2013 and provided an update on...
|
|
Peregrine Pharmaceuticals Announces Significant Progress in Advancing Its Cotara Program Into a Pivotal Phase III Trial
Dec 5, 2012
|
18.7 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 12/05/12 --
Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it has made significant progress in advancing its Cotara program into late-stage development through its agreement ...
|
|
Peregrine to Report Second Quarter Fiscal Year 2013 Financial Results After Market Close on December 10, 2012
Dec 3, 2012
|
14.8 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 12/03/12 --
Peregrine Pharmaceuticals (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it will report financial results for the second quarter of the fiscal year 2013 on December 10, 2012...
|
|
Peregrine Pharmaceuticals Announces Receipt of Notice From NASDAQ
Nov 14, 2012
|
13.4 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 11/14/12 --
Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, announced that it received today a notice from The NASDAQ Stock Market indicating that the company's minimum bid price has fallen below ...
|
|
New Data Support Ability of PS-Targeting Antibodies to Specifically Target Tumors and Stimulate Cancer-Fighting Immune Responses
Oct 31, 2012
|
20.0 KB |
|
| |
TUSTIN, CA -- (Marketwire) -- 10/31/12 --
Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the presentation of preclinical data showing specific localization and enhancement of anti-tumor functions of immune cel...
|
|
|
